INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
80 hedge funds and large institutions have $214M invested in Inozyme Pharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
2.34% more ownership
Funds ownership: 78.93% → 81.27% (+2.3%)
4% more capital invested
Capital invested by funds: $205M → $214M (+$9.18M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
80
Holding in Top 10
1
Calls
$1.44M
Puts
$100K
Top Buyers
| 1 | +$5.41M | |
| 2 | +$3.42M | |
| 3 | +$2.16M | |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.4M |
| 5 |
Goldman Sachs
New York
|
+$1.32M |
Top Sellers
| 1 | -$3.83M | |
| 2 | -$2.94M | |
| 3 | -$1.77M | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$866K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$822K |